TITLE

Salix Cancels Tax Inversion, Opens Way For Buyers

AUTHOR(S)
AMY REEVES
PUB. DATE
October 2014
SOURCE
Investors Business Daily;10/3/2014, p00
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
Specialty drugmaker
ACCESSION #
98664506

 

Related Articles

  • Salix deal underwhelms Street. Investor's Business Daily // Investors Business Daily;7/10/2014, pA02 

    Specialty drugmaker and IBD 50 stock

  • Santarus Buy Sparks Big Growth At Salix. KEN SHREVE // Investors Business Daily;5/16/2014, pB05 

    There's nothing better than when a stock's fundamentals and technicals tell a bullish story. When it happens — and the market is in an uptrend — the chances for a profitable investment increase significantly.

  • More Stock Leaders Emerge From More Industry Groups. DAVID SAITO-CHUNG // Investors Business Daily;6/6/2014, pB05 

    The set of 16 charts on IBD Stock Spotlight's computer-run screen are showing two promising new trends.

  • Ambarella Paces Sector Leaders, Hits New High. SCOTT STODDARD // Investors Business Daily;9/24/2014, pB08 

    A handful of leading stocks are holding up well even though the market's uptrend has once again come under

  • FleetCor, Salix Erase Big Gains From Buy Points. VINCENT MAO // Investors Business Daily;10/9/2014, pB06 

    With the market in correction mode, investors have to watch out for stocks setting off sell signals.

  • Bloomberg Blasts NYSE Again. Schroeder, Mary // Securities Industry News;3/3/2003, Vol. 15 Issue 9, p18 

    Reports that the U.S.-based securities dealing company, Bloomberg LP has objected to the New York Stock Exchange's proposed product called Liquidity Quote. Reasons for objecting to Liquity Quote by Bloomberg.

  • Salix Pharmaceuticals, Ltd. SWOT Analysis.  // Salix Pharmaceuticals, Ltd. SWOT Analysis;9/ 1/2014, p1 

    A SWOT analysis of Salix Pharmaceuticals Ltd. is presented.

  • Health Care M&A at Risk from Tax-Inversion Deal Rules. Fest, Glen // Mergers & Acquisitions Report;10/13/2014, Vol. 29 Issue 50, p1 

    New rules from the U.S. Department of the Treasury have already prompted the cancellation of Salix Pharmaceutical's $2.7 billion proposed acquisition of Cosmo Technologies

  • Salix Pharmaceuticals. Investor's Business Daily // Investors Business Daily;10/8/2014, pA02 

    The article reports that Salix Pharmaceuticals Ltd. closed down 2.4% as of October 10, 2014.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics